Izokibep Phase 2 in active PsA at Wk 16 results (80mg dose): ⭐️ACR50 52% ⭐️PASI 90 50% ⭐️Resolution of enthesitis LEI 88% ⭐️Safety profile similar to what observed in PsO. Promising for the enthesitis domain! @RheumNow OP0258 #EULAR2022 https://t.co/Wm3MvVQzoP